Stability and antigenicity of Chlamydia muridarum major outer membrane protein antigen at body temperature.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
      Chlamydia muridarum*/immunology ; Antigens, Bacterial*/immunology ; Chlamydia Infections*/immunology ; Chlamydia Infections*/prevention & control ; Bacterial Outer Membrane Proteins*/immunology ; Bacterial Vaccines*/immunology ; Bacterial Vaccines*/administration & dosage ; Antibodies, Bacterial*/immunology ; Antibodies, Bacterial*/blood; Animals ; Female ; Mice ; Body Temperature ; Mice, Inbred BALB C ; Protein Stability ; Immunity, Cellular ; Temperature ; Recombinant Proteins/immunology
    • Abstract:
      Chlamydia is an obligate intracellular bacterial pathogen responsible for disease and infertility across multiple species. Currently vaccines are being studied to help reduce the prevalence of this disease. The main advantage of protein subunit vaccines is their high degree of safety although this is traded off with the requirement for multiple booster doses to achieve complete protection. Although in certain populations the booster dose can be difficult and costly to administer, development of delayed vaccine delivery techniques, such as a vaccine capsule, could be the solution to this problem. One of the main drawbacks in this technology is that the antigen must remain stable at body temperature (37 °C) until release is achieved. Here we elucidate the stability of a recombinant chlamydial major outer membrane protein (MOMP) antigen and assess its antigenic and immunogenic properties after subjecting the antigen to 37 °C for four to six weeks. Through in vitro and in vivo assessment we found that the aged chlamydial MOMP was able to produce equivalent humoral and cell-mediated immune responses when compared with the unaged vaccine. It was also found that vaccines formulated with the aged antigen conferred equivalent protection against a live infection challenge as the unaged antigen. Thus ageing chlamydial MOMP antigens at 37 °C for four to six weeks did not cause any significant structural or antigenic/immunogenic degradation and recombinant C. muridarum MOMP is suitable for use in a delayed vaccine delivery system.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
    • Contributed Indexing:
      Keywords: Antigenicity; Booster dose; Delayed vaccine delivery; Subunit vaccine; Thermal stability
    • Accession Number:
      0 (Antigens, Bacterial)
      0 (Bacterial Outer Membrane Proteins)
      0 (Bacterial Vaccines)
      0 (Antibodies, Bacterial)
      0 (Recombinant Proteins)
    • Publication Date:
      Date Created: 20240619 Date Completed: 20240913 Latest Revision: 20240913
    • Publication Date:
      20240914
    • Accession Number:
      10.1016/j.vaccine.2024.06.015
    • Accession Number:
      38897891